AHR and psoriasis: In a model of imiquimod-induced psoriasis, AhR-deficient mice had exacerbated skin inflammation (Di Meglio et al., 2014), while topical application of the AhR agonists FICZ (Di Meglio et al., 2014) or Tapinarof (Smith et al., 2017) ameliorated disease symptoms.